Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Prevalence of Neurodegenerative Diseases
4.1.1.2. Research and Development
4.1.2. Restraints
4.1.2.1. The Stringent Developmental Regulations
4.1.2.2. Patent Expiry
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Indication Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type Segment
7.1.2. Market Attractiveness Index, By Indication Type Segment
7.2. Parkinson’s Disease
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Amyotrophic Lateral Sclerosis
7.4. Alzheimer’s Disease
7.5. Huntington Disease
7.6. Others
8. By Drug Type
8.1. Introduction
8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
8.1.2. Market Attractiveness Index, By Drug Type Segment
8.2. N-methyl-D-aspartate Receptor
8.2.1. Introduction
8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.3. Selective Serotonin Reuptake Inhibitor
8.4. Dopamine Inhibitors
8.5. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User Segment
9.2. Hospitals and Clinics
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Other
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. The U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. The U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
12. Company Profiles
12.1. Novartis
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AbbVie Inc.
12.3. Amneal Pharmaceuticals Inc.
12.4. Boehringer Ingelheim International GmbH
12.5. F. Hoffmann-La Roche Ltd.
12.6. GlaxoSmithKline PLC
12.7. Merck & Co. Inc.
12.8. Pfizer Inc.
12.9. Teva Pharmaceutical
12.10. UCB SA
LIST NOT EXHAUSTIVE
13. DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us